NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.
The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...
The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...
XI'AN, China, June 25, 2025 /PRNewswire/ -- Recently, LONGi's Hi-MO X10 series products have won the Class A certification for shadow resistance from Germany's...
HD Korea Shipbuilding & Offshore Engineering, HD Europe Research & Development Center, and HD Hydrogen signs Joint Development Project (JDP) agreement with European classification...